Antigenic mapping and functional characterization of human new world hantavirus neutralizing antibodies

  1. Taylor B Engdahl
  2. Elad Binshtein
  3. Rebecca L Brocato
  4. Natalia A Kuzmina
  5. Lucia M Principe
  6. Steven A Kwilas
  7. Robert K Kim
  8. Nathaniel S Chapman
  9. Monique S Porter
  10. Pablo Guardado-Calvo
  11. Félix A Rey
  12. Laura S Handal
  13. Summer M Diaz
  14. Irene A Zagol-Ikapitte
  15. Minh H Tran
  16. W Hayes McDonald
  17. Jens Meiler
  18. Joseph X Reidy
  19. Andrew Trivette
  20. Alexander Bukreyev
  21. Jay W Hooper  Is a corresponding author
  22. James E Crowe Jr.  Is a corresponding author
  1. Vanderbilt University, United States
  2. Vanderbilt University Medical Center, United States
  3. United States Army Medical Research Institute of Infectious Diseases, United States
  4. The University of Texas Medical Branch at Galveston, United States
  5. Institut Pasteur, CNRS UMR 3569, France

Abstract

Hantaviruses are high-priority emerging pathogens carried by rodents and transmitted to humans by aerosolized excreta or, in rare cases, person-to-person contact. While infections in humans are relatively rare, mortality rates range from 1 to 40% depending on the hantavirus species. There are currently no FDA-approved vaccines or therapeutics for hantaviruses, and the only treatment for infection is supportive care for respiratory or kidney failure. Additionally, the human humoral immune response to hantavirus infection is incompletely understood, especially the location of major antigenic sites on the viral glycoproteins and conserved neutralizing epitopes. Here, we report antigenic mapping and functional characterization for four neutralizing hantavirus antibodies. The broadly neutralizing antibody SNV-53 targets an interface between Gn/Gc, neutralizes through fusion inhibition and cross-protects against the Old World hantavirus species Hantaan virus when administered pre- or post-exposure. Another broad antibody, SNV-24, also neutralizes through fusion inhibition but targets domain I of Gc and demonstrates weak neutralizing activity to authentic hantaviruses. ANDV-specific, neutralizing antibodies (ANDV-5 and ANDV-34) neutralize through attachment blocking and protect against hantavirus cardiopulmonary syndrome (HCPS) in animals but target two different antigenic faces on the head domain of Gn. Determining the antigenic sites for neutralizing antibodies will contribute to further therapeutic development for hantavirus-related diseases and inform the design of new broadly protective hantavirus vaccines.

Data availability

All data generated or analyzed during this study are included in the manuscript.

Article and author information

Author details

  1. Taylor B Engdahl

    Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6280-4405
  2. Elad Binshtein

    Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, United States
    Competing interests
    No competing interests declared.
  3. Rebecca L Brocato

    Virology Division, United States Army Medical Research Institute of Infectious Diseases, Ft Detrick, United States
    Competing interests
    No competing interests declared.
  4. Natalia A Kuzmina

    Department of Pathology, The University of Texas Medical Branch at Galveston, Galveston, United States
    Competing interests
    No competing interests declared.
  5. Lucia M Principe

    Virology Division, United States Army Medical Research Institute of Infectious Diseases, Ft Detrick, United States
    Competing interests
    No competing interests declared.
  6. Steven A Kwilas

    Virology Division, United States Army Medical Research Institute of Infectious Diseases, Ft Detrick, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0383-3879
  7. Robert K Kim

    Virology Division, United States Army Medical Research Institute of Infectious Diseases, Ft Detrick, United States
    Competing interests
    No competing interests declared.
  8. Nathaniel S Chapman

    Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, United States
    Competing interests
    No competing interests declared.
  9. Monique S Porter

    Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, United States
    Competing interests
    No competing interests declared.
  10. Pablo Guardado-Calvo

    Virology Department, Institut Pasteur, CNRS UMR 3569, Paris, France
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7292-5270
  11. Félix A Rey

    Virology Department, Institut Pasteur, CNRS UMR 3569, Paris, France
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9953-7988
  12. Laura S Handal

    Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, United States
    Competing interests
    No competing interests declared.
  13. Summer M Diaz

    Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, United States
    Competing interests
    No competing interests declared.
  14. Irene A Zagol-Ikapitte

    Department of Biochemistry, Vanderbilt University, Nashville, United States
    Competing interests
    No competing interests declared.
  15. Minh H Tran

    Department of Biochemistry, Vanderbilt University, Nashville, United States
    Competing interests
    No competing interests declared.
  16. W Hayes McDonald

    Department of Biochemistry, Vanderbilt University, Nashville, United States
    Competing interests
    No competing interests declared.
  17. Jens Meiler

    Department of Chemistry, Vanderbilt University, Nashville, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8945-193X
  18. Joseph X Reidy

    Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, United States
    Competing interests
    No competing interests declared.
  19. Andrew Trivette

    Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, United States
    Competing interests
    No competing interests declared.
  20. Alexander Bukreyev

    Department of Pathology, The University of Texas Medical Branch at Galveston, Galveston, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0342-4824
  21. Jay W Hooper

    Virology Division, United States Army Medical Research Institute of Infectious Diseases, Ft Detrick, United States
    For correspondence
    jay.w.hooper.civ@mail.mil
    Competing interests
    No competing interests declared.
  22. James E Crowe Jr.

    Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, United States
    For correspondence
    james.crowe@vanderbilt.edu
    Competing interests
    James E Crowe, has served as a consultant for Luna Labs USA, Merck Sharp & Dohme Corporation, Emergent Biosolutions, GlaxoSmithKline and BTG International Inc, is a member of the Scientific Advisory Board of Meissa Vaccines, a former member of the Scientific Advisory Board of Gigagen (Grifols) and is founder of IDBiologics. The laboratory of J.E.C. received unrelated sponsored research agreements from AstraZeneca, Takeda, and IDBiologics during the conduct of the study..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0049-1079

Funding

National Institute of Allergy and Infectious Diseases (5T32GM008320)

  • Taylor B Engdahl

Military Infectious Diseases Program (MI210048)

  • Jay W Hooper

NIH Office of the Director (S10 OD030292)

  • James E Crowe Jr.

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Animal challenge studies were conducted in the ABSL-4 facility of the Galveston National Laboratory. The animal protocol for testing of mAbs in hamsters was approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Texas Medical Branch at Galveston (UTMB) (protocol #1912091).

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 1,765
    views
  • 290
    downloads
  • 18
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Taylor B Engdahl
  2. Elad Binshtein
  3. Rebecca L Brocato
  4. Natalia A Kuzmina
  5. Lucia M Principe
  6. Steven A Kwilas
  7. Robert K Kim
  8. Nathaniel S Chapman
  9. Monique S Porter
  10. Pablo Guardado-Calvo
  11. Félix A Rey
  12. Laura S Handal
  13. Summer M Diaz
  14. Irene A Zagol-Ikapitte
  15. Minh H Tran
  16. W Hayes McDonald
  17. Jens Meiler
  18. Joseph X Reidy
  19. Andrew Trivette
  20. Alexander Bukreyev
  21. Jay W Hooper
  22. James E Crowe Jr.
(2023)
Antigenic mapping and functional characterization of human new world hantavirus neutralizing antibodies
eLife 12:e81743.
https://doi.org/10.7554/eLife.81743

Share this article

https://doi.org/10.7554/eLife.81743

Further reading

    1. Immunology and Inflammation
    2. Neuroscience
    Jeremy M Shea, Saul A Villeda
    Research Article

    During aging, microglia – the resident macrophages of the brain – exhibit altered phenotypes and contribute to age-related neuroinflammation. While numerous hallmarks of age-related microglia have been elucidated, the progression from homeostasis to dysfunction during the aging process remains unresolved. To bridge this gap in knowledge, we undertook complementary cellular and molecular analyses of microglia in the mouse hippocampus across the adult lifespan and in the experimental aging model of heterochronic parabiosis. Single-cell RNA-Seq and pseudotime analysis revealed age-related transcriptional heterogeneity in hippocampal microglia and identified intermediate states of microglial aging that also emerge following heterochronic parabiosis. We tested the functionality of intermediate stress response states via TGFβ1 and translational states using pharmacological approaches in vitro to reveal their modulation of the progression to an activated state. Furthermore, we utilized single-cell RNA-Seq in conjunction with in vivo adult microglia-specific Tgfb1 conditional genetic knockout mouse models to demonstrate that microglia advancement through intermediate aging states drives transcriptional inflammatory activation and hippocampal-dependent cognitive decline.

    1. Immunology and Inflammation
    Mohsen Khosravi-Maharlooei, Andrea Vecchione ... Megan Sykes
    Research Article

    Human immune system (HIS) mice constructed in various ways are widely used for investigations of human immune responses to pathogens, transplants, and immunotherapies. In HIS mice that generate T cells de novo from hematopoietic progenitors, T cell-dependent multisystem autoimmune disease occurs, most rapidly when the human T cells develop in the native NOD.Cg- Prkdcscid Il2rgtm1Wjl (NSG) mouse thymus, where negative selection is abnormal. Disease develops very late when human T cells develop in human fetal thymus grafts, where robust negative selection is observed. We demonstrate here that PD-1+CD4+ peripheral (Tph) helper-like and follicular (Tfh) helper-like T cells developing in HIS mice can induce autoimmune disease. Tfh-like cells were more prominent in HIS mice with a mouse thymus, in which the highest levels of IgG were detected in plasma, compared to those with a human thymus. While circulating IgG and IgM antibodies were autoreactive to multiple mouse antigens, in vivo depletion of B cells and antibodies did not delay the development of autoimmune disease. Conversely, adoptive transfer of enriched Tfh- or Tph-like cells induced disease and autoimmunity-associated B cell phenotypes in recipient mice containing autologous human APCs without T cells. Tfh/Tph cells from mice with a human thymus expanded and induced disease more rapidly than those originating in a murine thymus, implicating HLA-restricted T cell-APC interactions in this process. Since Tfh, Tph, autoantibodies, and lymphopenia-induced proliferation (LIP) have all been implicated in various forms of human autoimmune disease, the observations here provide a platform for the further dissection of human autoimmune disease mechanisms and therapies.